Guggenheim Maintains Buy Rating on Neurocrine Biosciences Following Investor Meeting
On June 4, analysts at Guggenheim reiterated their Buy rating for Neurocrine Biosciences, Inc. (NASDAQ:NBIX), keeping their price target at $165.
Neurocrine Biosciences Inc (NBIX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 2,502,697 | $276,798,288 | +1% | 0.42% |
| 2. | Deerfield Management James E. Flynn | 1,489,000 | $164,683,400 | +73% | 3.25% |
| 3. | Braidwell LP Alex Karnal | 1,191,925 | $131,826,905 | +33% | 4.63% |
| 4. | AQR Capital Management Cliff Asness | 1,074,630 | $118,854,028 | -44% | 0.12% |
| 5. | Armistice Capital Steven Boyd | 1,000,190 | $110,621,014 | +13% | 1.66% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.96 | 22,300 | $132,796.50 | 3,527,700 | 2011-10-12 | Filing | |
| $5.96 | 1,000 | $5,955.00 | 757,600 | 2011-10-12 | Filing | |
| $5.96 | 6,200 | $36,921.00 | 1,236,665 | 2011-10-12 | Filing | |
| $5.73 | 3,800 | $21,768.30 | 3,505,400 | 2011-10-11 | Filing | |
| $5.59 | 44,700 | $249,779.13 | 3,501,600 | 2011-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $120.38 | 9,613 | $1,157,211.02 | 514,596 | 2025-05-27 | Filing | |
| $110.20 | 30,000 | $3,305,952.00 | 37,491 | 2025-05-05 | Filing | |
| $116.80 | 755 | $88,183.09 | 20,190 | 2025-02-13 | Filing | |
| $116.77 | 796 | $92,946.05 | 19,544 | 2025-02-13 | Filing | |
| $116.68 | 3,012 | $351,449.80 | 524,209 | 2025-02-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,682,394 | $1,623,872,774 | 0.03% | |
| 2. | 9,941,887 | $1,099,572,701 | 0.02% | |
| 3. | 5,534,624 | $612,129,414 | 0.35% | |
| 4. | 4,862,116 | $537,750,030 | 0.02% | |
| 5. | 2,670,998 | $295,412,423 | 0.02% |
News See All
15 Small-Cap Healthcare Stocks Hedge Funds Are Buying
The U.S. healthcare sector has performed better in 2025 compared to the broader market. After two years of weak performance, the healthcare sector kicked off on a strong note in 2025.
Billionaire Ken Griffin's 10 Midcap Stock Picks with Huge Upside Potential
Ken Griffin, the founder of Citadel, is an influential albeit controversial figure in the investment industry.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to Neurocrine Biosciences Reports First Quarter 2025 Results. At this time, all participants are in a listen only mode.
Billionaire Cliff Asness' 10 Stock Picks with Huge Upside Potential
Cliff Asness, the founder, managing principal, and chief investment officer of AQR Capital Management, is a well-known figure in the world of finance.
15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
15 Best Fast Growth Stocks To Buy Right Now
In the fourth quarter of 2024, the US Gross Domestic Product (GDP) expanded at an annual rate of 2.3%, slightly below market expectations of 2.7% and a deceleration from the 3.1% growth observed in the...
10 Top Insider Stock Buys And Sells In January
Ever heard of the “January effect?” In case you haven’t, a “January effect” is considered a phenomenon in the stock market where stock prices, most commonly of small-cap stocks, rise in the ...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2024 Earnings Call Transcript February 6, 2025Neurocrine Biosciences, Inc. misses on earnings expectations.